XML 30 R20.htm IDEA: XBRL DOCUMENT
v3.8.0.1

6. SALE OF STOCK (Sept. 2017 Note) | 3 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2017 | Jun. 30, 2017
Equity [Abstract] |  |
SALE OF STOCK | On August 22, 2017, the Company entered into agreements with accredited investors for the sale and purchase of 466,668 unregistered shares of its common stock, $0.01 par value at a purchase price of $0.45 per share. The Company received $210,001 in gross proceeds from the offering. The Company is using the net proceeds from this placement for general working capital purposes. Concurrently with the placement, the Company entered into an agreement with an investor for the sale of 88,888 unregistered shares of its common stock for services provided to the Company at a price of $0.45 per share. In connection with the placement, the Company also entered into a registration rights agreement with the investors, whereby the Company is obligated to file a registration statement with the Securities Exchange Commission on or before 90 calendar days after August 22, 2017 to register the resale by the investors of 555,556 shares of our common stock purchased in the placement. |
(a) | Stock Options
Stock-based compensation costs recognized during the year ended June 30, 2017 and 2016 amounted to $201,612 and $241,388 respectively, and were included in the accompanying consolidated statements of operations in: selling, general and administrative expenses (2017 — $134,984; 2016 — $123,370), cost of goods sold (2017 — $34,676; 2016 — $60,680), and research and development expenses, net (2017 — $31,952; 2016 — $57,338). No compensation has been capitalized because such amounts would have been immaterial. There was no net income tax benefit recognized related to such compensation for the years ended June 30, 2017 or 2016, as the Company is currently in a loss position. There were 15,000 stock options granted during the year ended June 30, 2017 and 160,000 stock options granted during the year ended June 30, 2016. As of June 30, 2017, the unrecognized compensation costs related to options vesting in the future is $0. The Company uses the Black-Scholes option-pricing model as the most appropriate method for determining the estimated fair value for the stock awards. The Black-Scholes method of valuation requires several assumptions: (1) the expected term of the stock award; (2) the expected future stock volatility over the expected term; and (3) risk-free interest rate. The expected term represents the expected period of time the Company believes the options will be outstanding based on historical information. Estimates of expected future stock price volatility are based on the historic volatility of the Company’s common stock and the risk-free interest rate is based on the U.S. Zero-Bond rate. The Company utilizes a forfeiture rate based on an analysis of the Company’s actual experience. The fair value of options at date of grant was estimated with the following assumptions for options granted in fiscal 2017:
|  | Year Ended |
|  | June 30, 2017 |
Assumptions: |  |  |  |
Option life |  |  | 5.3 years |
Risk-free interest rate |  |  | 1.01% |
Stock volatility |  |  | 175% |
Dividend yield |  |  | 0 |
Weighted average fair value of grants |  | $ | 0.38 |
Stock Option and Other Compensation Plans: The type of share-based payments currently utilized by the Company is stock options. The Company has various stock option and other compensation plans for directors, officers and employees. The Company has the following stock option plans outstanding as of June 30, 2017: The Precision Optics Corporation, Inc. 2011 Equity Incentive Plan (the “2011 Plan”); the Precision Optics Corporation, Inc. 2006 Equity Incentive Plan (the “2006 Plan”), and the Precision Optics Corporation, Inc. Amended and Restated 1997 Incentive Plan (the “1997 Plan”). Vesting periods under the 2011 Plan, the 2006 Plan, and the 1997 Plan are at the discretion of the Board of Directors and typically average three to five years. Options under these Plans are granted at fair market value on the date of grant and typically have a term of ten years from the date of grant. The 2011 Plan, which provides eligible participants (certain employees, directors, consultants, etc.) the opportunity to receive a broad variety of equity based and cash awards. Options granted vest and are exercisable for periods determined by the Board of Directors, not to exceed 10 years from the date of grant. On April 16, 2015, the Board of Directors approved an amendment to the 2011 Equity Incentive Plan which increased the maximum number of shares of the Company’s common stock that may be awarded under the Plan from 325,000 to 1,825,000, an increase of 1,500,000 shares. In connection therewith, on April 20, 2015, the Company filed a registration statement on Form S-8 to register the 1,500,000 shares of the Company’s common stock. At June 30, 2017, a total of 954,602 stock options are outstanding and 870,398 shares of common stock were available for future grants under the 2011 Plan. The 2006 Plan, which provides eligible participants (certain employees, directors, consultants, etc.) the opportunity to receive a broad variety of equity based and cash awards. Options granted vest and are exercisable for periods determined by the Board of Directors, not to exceed 10 years from the date of grant. A total of 139,898 shares of common stock, including shares rolled forward from the 1997 Plan, have been reserved for issuance under the 2006 Plan. At June 30, 2017, a total of 123,798 stock options are outstanding, 23,100 stock options have been cancelled and no shares of common stock are available for future grants under the 2006 Plan. The 1997 Plan as amended and restated in 2006 provided eligible participants (certain employees, directors, consultants, etc.) the opportunity to receive a broad variety of equity based and cash awards. Options granted vested and were exercisable for periods determined by the Board of Directors, not to exceed 10 years from the date of grant. All stock options outstanding under the 1997 Plan expired during fiscal 2016, no options are outstanding under the 1997 Plan at June 30, 2017, and no shares of common stock are available for future grants under the 1997 Plan. The following tables summarize stock option activity for the years ended June 30, 2017 and 2016:
|  | Options Outstanding
|  | Number of Shares |  |  | Weighted Average Exercise Price |  |  | Weighted Average Contractual Life
Outstanding at July 1, 2015 |  |  | 1,079,079 |  |  | $ | 1.43 |  |  | 8.46 years
Grants |  |  | 160,000 |  |  | $ | 0.49 |  |  |
Cancellations |  |  | (103,079 | ) |  | $ | 7.03 |  |  |
Outstanding at June 30, 2016 |  |  | 1,136,000 |  |  | $ | 0.79 |  |  | 8.00 years
Grants |  |  | 15,000 |  |  | $ | 0.40 |  |  |
Cancellations |  |  | (72,600 | ) |  | $ | 0.85 |  |  |
Outstanding at June 30, 2017 |  |  | 1,078,400 |  |  | $ | 0.78 |  |  | 7.01 years
Information related to the stock options outstanding as of June 30, 2017 is as follows:
Range of Exercise Prices |  |  | Number of Shares |  |  | Weighted- Average Remaining Contractual Life (years) |  |  | Weighted- Average Exercise Price |  |  | Exercisable Number of Shares |  |  | Exercisable Weighted- Average Exercise Price |
$ | 0.27 |  |  |  | 40,000 |  |  |  | 4.04 |  |  | $ | 0.27 |  |  |  | 40,000 |  |  | $ | 0.27 |
$ | 0.40 |  |  |  | 15,000 |  |  |  | 9.83 |  |  | $ | 0.40 |  |  |  | 5,000 |  |  | $ | 0.40 |
$ | 0.48 |  |  |  | 60,000 |  |  |  | 8.75 |  |  | $ | 0.48 |  |  |  | 40,000 |  |  | $ | 0.48 |
$ | 0.50 |  |  |  | 100,000 |  |  |  | 8.98 |  |  | $ | 0.50 |  |  |  | 65,000 |  |  | $ | 0.50 |
$ | 0.55 |  |  |  | 29,500 |  |  |  | 4.62 |  |  | $ | 0.55 |  |  |  | 29,500 |  |  | $ | 0.55 |
$ | 0.73 |  |  |  | 539,500 |  |  |  | 7.88 |  |  | $ | 0.73 |  |  |  | 479,500 |  |  | $ | 0.73 |
$ | 0.85 |  |  |  | 9,000 |  |  |  | 5.51 |  |  | $ | 0.85 |  |  |  | 9,000 |  |  | $ | 0.85 |
$ | 0.90 |  |  |  | 9,000 |  |  |  | 6.51 |  |  | $ | 0.90 |  |  |  | 9,000 |  |  | $ | 0.90 |
$ | 0.95 |  |  |  | 65,000 |  |  |  | 7.03 |  |  | $ | 0.95 |  |  |  | 65,000 |  |  | $ | 0.95 |
$ | 1.20 |  |  |  | 207,800 |  |  |  | 4.67 |  |  | $ | 1.20 |  |  |  | 207,800 |  |  | $ | 1.20 |
$ | 1.25 |  |  |  | 1,200 |  |  |  | 1.41 |  |  | $ | 1.25 |  |  |  | 1,200 |  |  | $ | 1.25 |
$ | 1.35 |  |  |  | 1,200 |  |  |  | 2.40 |  |  | $ | 1.35 |  |  |  | 1,200 |  |  | $ | 1.35 |
$ | 7.75 |  |  |  | 1,200 |  |  |  | 0.41 |  |  | $ | 7.75 |  |  |  | 1,200 |  |  | $ | 7.75 |
$ | 0.27–7.75 |  |  |  | 1,078,400 |  |  |  | 7.01 |  |  | $ | 0.78 |  |  |  | 953,400 |  |  | $ | 0.81 |
The aggregate intrinsic value of the Company’s “in-the-money” outstanding and exercisable options as of June 30, 2017 was $34,875 and $26,975, respectively.
(b) | Warrants
As of June 30, 2017, there are warrants outstanding for the issuance of an aggregate of 3,661,560 shares of common stock, at a weighted average exercise price of $0.75 per share. Warrants for the issuance of 2,994,893 of these shares at an average exercise price of $0.87 per share expire on September 28, 2017, and warrants for the issuance of the remaining 666,667 shares at an exercise price $0.01 per share expire on October 16, 2017.
(c) | Sale of Stock in October 2015
On October 19, 2015, the Company entered into agreements with accredited investors for the sale and purchase of 1,044,776 shares of the Company’s common stock, $0.01 par value at a purchase price of $0.67 per share. The Company received $700,000 in gross proceeds from the offering. The Company used the majority of the net proceeds from this placement for general working capital purposes. In conjunction with the placement, the Company also entered into a registration rights agreement with the investors, and in compliance with the terms of the agreement the registration statement was filed on January 19, 2016 and became effective on February 1, 2016. In conjunction with the 2015 offering, certain anti-dilution provisions of the warrants issued in conjunction with the Company’s June 25, 2008 and September 28, 2012 financing transactions were triggered. As a result of the offering, the number of existing September 28, 2012 warrants increased from 2,189,724 to 2,293,013 and from 217,322 to 222,559, respectively, and the related exercise price decreased from $1.11 to $1.06 and from $0.85 to $0.83, respectively.
(d) | Sale of Stock in November 2016
On November 22, 2016, the Company entered into agreements with accredited investors for the sale and purchase of 1,333,334 units with each unit consisting of one share of the Company’s common stock, $0.01 par value and one warrant to purchase one-half of one share of the Company’s common stock, at a purchase price of $0.60 per unit. The Company received $780,000 in gross cash proceeds from the offering and settled an outstanding accounts payable balance with a consultant in the amount of $20,000 by issuing units. The Company is using the net proceeds from this placement for general working capital purposes. The warrants issued in this offering will vest on October 2, 2017 and expire on October 16, 2017. The warrant exercise price is variable and depends on the Company’s achievement of certain performance criteria. The warrant exercise price was agreed to be $0.40 per share if the Company achieved both of the revenue and income performance criteria as defined, the exercise price would be $0.20 per share if the Company achieves one of the performance criteria, and the exercise price would be $0.01 if the Company did not achieve either of the performance criteria. Since the Company did not achieve either of the criteria, the exercise price of the warrants is $0.01. In conjunction with the offering, the Company also entered into a registration rights agreement with the investors, whereby the Company was obligated to file a registration statement with the Securities Exchange Commission on or before 90 calendar days after November 22, 2016 to register the resale by the investors of the 1,333,334 shares and warrant shares purchased in the offering. The registration statement was filed with the Securities and Exchange Commission on February 3, 2017 and became effective on March 2, 2017. In conjunction with the 2016 offering, certain anti-dilution provisions of the warrants issued in conjunction with the Company’s September 28, 2012 financing transaction were triggered. As a result of the offering, the number of existing September 28, 2012 warrants increased from 2,293,013 to 2,558,519 and from 222,559 to 249,627, respectively, and the related exercise price decreased from $1.06 to $0.95 and from $0.83 to $0.74, respectively.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration